4.1 Article

Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV

期刊

HIV MEDICINE
卷 23, 期 3, 页码 274-286

出版社

WILEY
DOI: 10.1111/hiv.13211

关键词

all-cause mortality; Asian people living with HIV; HIV; AIDS; metabolic syndrome; weight gain

资金

  1. US National Institutes of Health's National Institute of Allergy and Infectious Diseases
  2. Eunice Kennedy Shriver National Institute of Child Health and Human Development
  3. National Cancer Institute
  4. National Institute of Mental Health
  5. National Institute on Drug Abuse
  6. National Heart, Lung, and Blood Institute
  7. National Institute on Alcohol Abuse and Alcoholism
  8. National Institute of Diabetes and Digestive and Kidney Diseases
  9. Fogarty International Center, as part of the International Epidemiology Databases to Evaluate AIDS (IeDEA) [U01AI069907]
  10. Australian Government Department of Health and Ageing

向作者/读者索取更多资源

Among Asian adults living with HIV, weight gain after initiation of antiretroviral therapy is significantly higher in individuals with lower CD4 count, higher HIV RNA, and those starting with an INSTI-based regimen. The development of MetS does not show a significant association with all-cause mortality.
Objectives We investigated weight changes following antiretroviral therapy (ART) initiation, the development of metabolic syndrome (MetS) and its association with all-cause mortality among Asian adults living with HIV. Methods Participants enrolled in a regional Asian HIV-infected cohort with weight and height measurements at ART initiation were eligible for inclusion in the analysis. Factors associated with weight changes and incident MetS (according to the International Diabetic Federation (IDF) definition) were analysed using linear mixed models and Cox regression, respectively. Competing-risk regression models were used to investigate the association of MetS with all-cause mortality. Results Among 4931 people living with HIV (PLWH), 66% were male. At ART initiation, the median age was 34 [interquartile range (IQR) 29-41] years, and the median (IQR) weight and body mass index (BMI) were 55 (48-63) kg and 20.5 (18.4-22.9) kg/m(2), respectively. At 1, 2 and 3 years of ART, overall mean (+/- standard deviation) weight gain was 2.2 (+/- 5.3), 3.0 (+/- 6.2) and 3.7 (+/- 6.5) kg, respectively. Participants with baseline CD4 count <= 200 cells/mu L [weight difference (diff) = 2.2 kg; 95% confidence interval (CI) 1.9-2.5 kg] and baseline HIV RNA >= 100 000 HIV-1 RNA copies/mL (diff = 0.6 kg; 95% CI 0.2-1.0 kg), and those starting with integrase strand transfer inhibitor (INSTI)-based ART (diff = 2.1 kg; 95% CI 0.7-3.5 kg vs. nonnucleoside reverse transcriptase inhibitors) had greater weight gain. After exclusion of those with abnormal baseline levels of MetS components, 295/3503 had incident MetS [1.18 (95% CI 1.05-1.32)/100 person-years (PY)]. The mortality rate was 0.7 (95% CI 0.6-0.8)/100 PY. MetS was not significantly associated with all-cause mortality in the adjusted model (P = 0.236). Conclusions Weight gain after ART initiation was significantly higher among those initiating ART with lower CD4 count, higher HIV RNA and an INSTI-based regimen after controlling for baseline BMI. Greater efforts to identify and manage MetS among PLWH are needed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据